Evidence map›Paper›PMID 32117098›Full record

ArticleFrontiers in microbiology2020

RcLS2F - A Novel Fungal Class 1 KDAC Co-repressor Complex in

Ingo Bauer, Silke Gross, Petra Merschak, Leopold Kremser, Betim Karahoda, Özlem Sarikaya Bayram, Beate Abt, Ulrike Binder, Fabio Gsaller, Herbert Lindner and 3 more

Abstract read
In one paragraph

Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ingo BauerInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Silke GrossInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Petra MerschakInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Leopold KremserInstitute of Clinical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Betim KarahodaBiology Department, Maynooth University, Maynooth, Ireland.
Özlem Sarikaya BayramBiology Department, Maynooth University, Maynooth, Ireland.
Beate AbtInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Ulrike BinderInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Fabio GsallerInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Herbert LindnerInstitute of Clinical Biochemistry, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Özgür BayramBiology Department, Maynooth University, Maynooth, Ireland.
Gerald BroschInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.
Stefan GraessleInstitute of Molecular Biology, Biocenter, Medical University of Innsbruck, Innsbruck, Austria.

Funding

Austrian Science Fund FWF P 24803
6 · The paper itself

Abstract

The fungal class 1 lysine deacetylase (KDAC) RpdA is a promising target for prevention and treatment of invasive fungal infection. RpdA is essential for survival of the most common air-borne mold pathogen

Indexed as

AscomycotaAspergillus nidulanscalciumchromatinco-repressor complexhistone deacetylase (HDAC)lysine deacetylase (KDAC)RpdA

Identifiers

PMID32117098
PMCPMC7010864

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.